KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Current Assets (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Current Assets for 16 consecutive years, with $94.5 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 25.81% to $94.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $94.5 million through Dec 2025, down 25.81% year-over-year, with the annual reading at $94.5 million for FY2025, 25.81% down from the prior year.
  • Current Assets hit $94.5 million in Q4 2025 for Arbutus Biopharma, down from $97.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $172.7 million in Q1 2022 to a low of $83.5 million in Q2 2021.
  • Historically, Current Assets has averaged $133.6 million across 5 years, with a median of $136.6 million in 2021.
  • Biggest five-year swings in Current Assets: surged 89.05% in 2022 and later plummeted 30.43% in 2025.
  • Year by year, Current Assets stood at $160.7 million in 2021, then fell by 5.93% to $151.1 million in 2022, then decreased by 12.65% to $132.0 million in 2023, then decreased by 3.57% to $127.3 million in 2024, then fell by 25.81% to $94.5 million in 2025.
  • Business Quant data shows Current Assets for ABUS at $94.5 million in Q4 2025, $97.4 million in Q3 2025, and $103.1 million in Q2 2025.